From FDA approvals streamlining access to critical therapies to new breakthroughs in challenging malignancies, the field of cancer care continues to demonstrate remarkable progress.

A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 7.26%. Read on to learn why. Crispr Therapeutics AG has seen a notable ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

Legend Biotech Corp. ADR advanced stock charts by Barron's. View LEGN historical stock data and compare to other stocks, and exchanges.

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.0, a high ...

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...

The long-term benefits of CAR T-cell therapy, the use of residual disease activity to direct treatment, and a novel drug ...

A Martin County family with a child fighting rare cancer is getting help from the community to get treatment abroad.